Skip to main content
NYSE:TEVA

Teva Pharmaceutical Industries Stock Forecast, Price & News

$10.57
+0.15 (+1.44 %)
(As of 05/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$10.48
$10.67
50-Day Range
$10.09
$11.58
52-Week Range
$8.44
$13.30
Volume186,130 shs
Average Volume9.48 million shs
Market Capitalization$11.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.49
30 days | 90 days | 365 days | Advanced Chart
Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.


Teva Pharmaceutical Industries logo

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171
Employees37,100
Year FoundedN/A

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$3.56 per share
Book Value$13.79 per share

Profitability

Net Income$-998,000,000.00

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares1,092,190,000
Market Cap$11.54 billion
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

422nd out of 2,039 stocks

Pharmaceutical Preparations Industry

187th out of 769 stocks

Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

Is Teva Pharmaceutical Industries a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries
or view top-rated stocks.

What stocks does MarketBeat like better than Teva Pharmaceutical Industries?

Wall Street analysts have given Teva Pharmaceutical Industries a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Teva Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest in March. As of March 31st, there was short interest totaling 25,040,000 shares, a decrease of 31.2% from the March 15th total of 36,370,000 shares. Based on an average trading volume of 9,260,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.3% of the company's shares are sold short.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Teva Pharmaceutical Industries
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings results on Wednesday, April, 28th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.08. The business earned $3.98 billion during the quarter, compared to analyst estimates of $4.04 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 19.32% and a negative net margin of 24.17%. Teva Pharmaceutical Industries's revenue for the quarter was down 8.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.76 EPS.
View Teva Pharmaceutical Industries' earnings history
.

How has Teva Pharmaceutical Industries' stock been impacted by Coronavirus (COVID-19)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has increased by 17.6% and is now trading at $10.60.
View which stocks have been most impacted by COVID-19
.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of 2.500-2.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.610. The company issued revenue guidance of $16.40 billion-$16.80 billion, compared to the consensus revenue estimate of $16.68 billion.

What price target have analysts set for TEVA?

11 equities research analysts have issued 12-month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.78 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kare Schultz, Pres, CEO & Director (Age 60, Pay $5.6M)
  • Mr. Eliyahu Sharon Kalif, Exec. VP & CFO (Age 48, Pay $655.76k)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 59, Pay $2.48M)
  • Mr. Brendan P. O'Grady, Exec. VP of North America Commercial (Age 54, Pay $1.56M)
  • Mr. Eric Drape, Exec. VP of Global Operations (Age 59)
  • Mr. Andrew J. Weil CPA, Chief Accounting Officer (Age 54)
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations
  • Mr. David M. Stark, Exec. VP & Chief Legal Officer (Age 52)
  • Ms. Lori Queisser, Sr. VP & Global Compliance Officer
  • Mr. Mark Sabag, Exec. VP, Chief HR Officer and Global Communications & Brand (Age 50)

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.84%), Migdal Insurance & Financial Holdings Ltd. (1.81%), Menora Mivtachim Holdings LTD. (1.50%), Capital International Investors (1.34%), Clal Insurance Enterprises Holdings Ltd (1.32%) and Phoenix Holdings Ltd. (1.06%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane and Sol J Barer.
View institutional ownership trends for Teva Pharmaceutical Industries
.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Capital International Investors, Credit Suisse AG, Russell Investments Group Ltd., Northern Trust Corp, Allianz Asset Management GmbH, and Bank of Montreal Can. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Mark Sabag, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries
or view top insider-selling stocks.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Phoenix Holdings Ltd., Eversept Partners LP, Menora Mivtachim Holdings LTD., Banque Pictet & Cie SA, Pictet North America Advisors SA, Private Management Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Teva Pharmaceutical Industries
or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $10.60.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries has a market capitalization of $11.58 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries employs 37,100 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Where are Teva Pharmaceutical Industries' headquarters?

Teva Pharmaceutical Industries is headquartered at 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.